Follow us on

Q of the week

Q: How Do You Get Shingles?

Get the Answer: 

Prototype devices

It is recognized that a manufacturer may wish to submit a small number  of "prototype models" of a device to clinical investigation in order to assess safety and/or performance; and those such prototypes may need to undergo a number of changes prior to large-scale production.
 Forums
Board Index Latest Posts Welcome Guest   [Register]  [Login]
EFGCP–EUCROF Joint Workshop Final Report   by  on 2010-08-20 20:12:20
Managing Clinical Trials   by  on 2010-07-16 00:05:32
US-FDA issues Revised Info Sheet Guidance on Clinical Investigator Disqualification   by  on 2010-06-13 18:11:41
US-FDA issues final guidance on Statement of Investigator (Form FDA 1572)   by  on 2010-06-13 18:07:59
Rising Clinical Trial Complexity Continues to Vex Drug Developers   by  on 2010-06-03 17:36:33
Investigator-Driven Clinical Trials: An ESF Forward Look   by  on 2010-06-03 17:27:58
NIH's Financial Conflict of Interest (FCOI) Proposed Rule   by  on 2010-05-27 19:42:00
AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population   by  on 2010-05-13 19:39:54
Argentina: ANMAT - new regulatory update   by  on 2010-05-01 09:40:32
The Wall Street Journal's special supplement on clinical trials   by  on 2010-05-01 09:31:52
Major developments in EU Clinical Trial Guidances   by  on 2010-04-21 03:10:55
Analysis of the adverse reactions induced by natural product-derived drugs   by  on 2010-04-19 07:16:06
Newer Antibacterial Drugs for a New Century   by  on 2010-04-19 06:49:47
Newer Non-Statin Drugs for Reducing Cholesterol   by  on 2010-04-13 15:57:20
Practice Guidelines for Chronic Pain Management   by  on 2010-04-05 04:52:16
CONSORT III (2010)   by  on 2010-03-29 20:53:28
US FDA Draft Guidance on Pharmacokinetics in Patients with Impaired Renal Function   by  on 2010-03-20 20:25:16
US-FDA issues First Draft Guidance on Noninferiority Trials   by  on 2010-03-04 22:07:46
US FDA new rule on reporting information regarding falsification of data   by  on 2010-02-26 04:47:33
US-FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials   by  on 2010-02-06 20:12:14
 Subject :Urgently Required Medical Director for an Early-Phase/Proof-of-Concept.. 2010-07-16 18:58:12 
Leon
Newbie
Joined: 2009-07-13 19:19:42
Posts: 23
Location: 
Subject :Urgently Required Medical Director for an Early-Phase/Proof-of-Concept(POC) Unit,India

Dear Friends,

Outstanding opportunity now available for a qualified leader to become the Medical Director of the Medanta Duke Research Institute (MDRI), an early-phase, Proof-of-Concept (POC) collaboration between Duke University and Medanta – The Medicity, a premier healthcare facility in Gurgaon, India. The Medical Director oversees a 60-bed POC unit within a new, state-of-the-art, 1,500-bed tertiary and multi-specialty quaternary care facility.  The Unit focuses on industry and academic biomedical research, and the Medical Director will provide strategic and operational oversight of all research and education/training activities. The Unit is poised to become a regional and global leader in providing innovative solutions to sponsors and investigators in early phase and POC clinical trials.  The applicant should be an MD (or equivalent) with at least 5 years experience in either academic or industry First-In-Man/Phase-I/Early-Phase/POC clinical research environments.  Additional education or training in Clinical Pharmacology is desired, not required.  Interested applicants should submit a cover letter and CV to MDRIemployment@duke.edu 

Please find attached document for details.

Kind regards,

Susan Clayton
Assistant to Robert M. Califf, MD
Vice Chancellor for Clinical Research
Duke University Medical Center
Director, Duke Translational Medicine Institute
1117 Davison Building, Box 3701
Durham, NC  27710
Tel:  (919) 668-8820
Fax: (919) 668-7103



Attachments
 FINAL MDRI Medical Director Recruitment.doc [23 KB] ::
IP Logged
Page # 


Powered by ccBoard